GeneDx (WGS) Financials

$39.24 -0.37 (-0.94%)

As of 02:30 PM Eastern

Annual Income Statements for GeneDx

This table shows GeneDx's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-33	-241	-245	-549	-176	-52	-21
Consolidated Net Income / (Loss)	-30	-241	-245	-549	-176	-52	-21
Net Income / (Loss) Continuing Operations	-30	-241	-245	-549	-176	-52	-21
Total Pre-Tax Income	-30	-241	-245	-598	-177	-53	-21
Total Operating Income	-30	-242	-446	-668	-181	-23	-13
Total Gross Profit	83	4.03	-17	-27	90	194	298
Total Revenue	196	179	212	235	203	305	428
Operating Revenue	196	179	212	235	203	305	428
Total Cost of Revenue	113	175	229	261	113	111	129
Operating Cost of Revenue	113	175	229	261	113	111	129
Total Operating Expenses	113	246	430	641	271	218	311
Selling, General & Admin Expense	29	101	206	216	139	105	151
Marketing Expense	39	63	113	122	61	67	88
Research & Development Expense	35	73	105	86	58	46	72
Other Operating Expenses / (Income)	9.45	9.40	5.66	6.31	1.96	0.00	0.00
Impairment Charge	-	0.00	0.00	210	10	0.00	0.00
Total Other Income / (Expense), net	0.71	0.65	201	70	3.90	-29	-8.06
Interest & Investment Income	0.99	0.51	0.08	-	1.11	-3.03	-2.54
Other Income / (Expense), net	0.50	2.62	204	70	2.79	-26	-5.52
Income Tax Expense	0.00	0.00	0.00	-49	-0.93	-0.34	-0.12
Basic Earnings per Share	($264,056.00)	($47,036.00)	($2.27)	($53.63)	($7.23)	($1.94)	($0.73)
Weighted Average Basic Shares Outstanding	124.00	5.13K	108.08M	10.24M	24.31M	26.89M	28.64M
Diluted Earnings per Share	($264,056.00)	($47,036.00)	($2.27)	($53.63)	($7.23)	($1.94)	($0.73)
Weighted Average Diluted Shares Outstanding	124.00	5.13K	108.08M	10.24M	24.31M	26.89M	28.64M
Weighted Average Basic & Diluted Shares Outstanding	-	-	244.96M	798.25M	26.05M	28.07M	29.29M

This table shows GeneDx's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-42	-26	-20	-29	-8.31	5.44	-6.53	11	-7.64	-18	-63
Consolidated Net Income / (Loss)	-42	-26	-20	-29	-8.31	5.44	-6.53	11	-7.64	-18	-63
Net Income / (Loss) Continuing Operations	-42	-26	-20	-29	-8.31	5.44	-6.53	11	-7.64	-18	-63
Total Pre-Tax Income	-42	-26	-20	-29	-8.36	5.41	-6.08	11	-7.39	-18	-62
Total Operating Income	-43	-26	-14	-11	-7.78	8.81	-4.55	8.96	-3.25	-14	-57
Total Gross Profit	25	31	37	43	48	66	58	71	85	84	68
Total Revenue	53	57	62	71	77	96	87	103	117	121	102
Operating Revenue	53	57	62	71	77	96	87	103	117	121	102
Total Cost of Revenue	28	27	25	28	29	29	29	32	32	37	34
Operating Cost of Revenue	28	27	25	28	29	29	29	32	32	37	34
Total Operating Expenses	68	56	51	54	56	57	63	62	88	99	126
Selling, General & Admin Expense	26	27	23	26	27	27	50	27	44	47	75
Research & Development Expense	14	12	12	11	12	12	13	15	20	25	20
Impairment Charge	8.28	-	-	-	-	-	0.00	-	-	-	31
Total Other Income / (Expense), net	0.51	-1.71	-6.66	-19	-0.58	-3.39	-1.53	1.60	-4.14	-4.00	-4.95
Interest Expense	-	-	-	-	-	-	0.00	-	-	-	6.57
Interest & Investment Income	1.05	-	-0.60	-0.89	-0.84	-	-0.64	-0.82	-0.56	-0.52	-0.72
Other Income / (Expense), net	-0.54	-0.73	-6.06	-18	0.26	-2.69	-0.89	2.42	-3.58	-3.48	2.33
Income Tax Expense	-0.17	-0.41	-0.08	-0.19	-0.05	-0.02	0.45	-0.25	0.25	-0.56	0.90
Basic Earnings per Share	($1.64)	($1.06)	($0.78)	($1.10)	($0.31)	$0.20	($0.23)	$0.38	($0.27)	($0.61)	($2.16)
Weighted Average Basic Shares Outstanding	25.79M	24.31M	26.06M	26.62M	27.10M	26.89M	28.15M	28.58M	28.80M	28.64M	29.34M
Diluted Earnings per Share	($1.64)	($1.06)	($0.78)	($1.10)	($0.31)	$0.20	($0.23)	$0.36	($0.27)	($0.59)	($2.16)
Weighted Average Diluted Shares Outstanding	25.79M	24.31M	26.06M	26.62M	27.10M	26.89M	28.15M	29.75M	28.80M	28.64M	29.34M
Weighted Average Basic & Diluted Shares Outstanding	25.88M	26.05M	26.14M	26.94M	27.47M	28.07M	28.53M	28.73M	28.90M	29.29M	29.69M

This table details how cash moves in and out of GeneDx's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	114	3.95	283	-263	-38	-14	20
Net Cash From Operating Activities	-19	-93	-190	-319	-180	-28	33
Net Cash From Continuing Operating Activities	-19	-93	-192	-319	-180	-28	33
Net Income / (Loss) Continuing Operations	-30	-241	-245	-549	-176	-52	-21
Consolidated Net Income / (Loss)	-30	-241	-245	-549	-176	-52	-21
Depreciation Expense	6.41	12	22	59	34	22	25
Non-Cash Adjustments To Reconcile Net Income	6.73	123	25	183	3.71	23	42
Changes in Operating Assets and Liabilities, net	-2.16	14	6.65	-13	-41	-21	-12
Net Cash From Investing Activities	-15	-32	-21	-141	-44	-30	-62
Net Cash From Continuing Investing Activities	-15	-32	-21	-141	-44	-30	-62
Purchase of Property, Plant & Equipment	-15	-32	-21	-14	-5.71	-5.49	-19
Acquisitions	-	0.00	0.00	-127	-12	0.00	-33
Purchase of Investments	-	-	-	0.00	-48	-66	-56
Sale of Property, Plant & Equipment	-	-	-	0.00	4.03	0.00	0.00
Sale and/or Maturity of Investments	-	-	-	0.00	18	42	46
Net Cash From Financing Activities	148	129	494	197	186	44	48
Net Cash From Continuing Financing Activities	148	129	498	197	186	44	48
Repayment of Debt	-1.71	-0.19	-10	0.00	-2.00	-0.50	-1.21
Issuance of Debt	0.00	16	0.00	0.00	49	0.00	0.00
Issuance of Common Equity	0.00	0.00	793	198	143	47	50
Other Financing Activities, net	31	-4.01	-2.46	-0.34	-3.31	-2.33	-0.43
Cash Interest Paid	0.31	1.75	2.75	1.93	3.04	6.68	6.41
Cash Income Taxes Paid	0.00	0.00	0.35	1.24	1.47	1.17	1.28

This table details how cash moves in and out of GeneDx's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	-69	12	-16	-28	1.82	27	14	-26	22	9.03	-11
Net Cash From Operating Activities	-41	-30	-16	-4.51	-4.40	-3.18	10	10	16	-3.09	-32
Net Cash From Continuing Operating Activities	-41	-30	-16	-4.51	-4.40	-3.45	10	10	16	-3.09	-32
Net Income / (Loss) Continuing Operations	-42	-26	-20	-29	-8.31	5.44	-6.53	11	-7.64	-18	-63
Consolidated Net Income / (Loss)	-42	-26	-20	-29	-8.31	5.44	-6.53	11	-7.64	-18	-63
Depreciation Expense	8.67	6.09	5.25	5.22	5.93	5.56	5.68	6.19	6.47	6.88	6.81
Non-Cash Adjustments To Reconcile Net Income	6.60	-2.74	5.46	22	2.89	-7.99	6.48	9.37	19	7.10	45
Changes in Operating Assets and Liabilities, net	-14	-7.44	-6.88	-2.85	-4.90	-6.45	4.56	-16	-1.63	0.60	-21
Net Cash From Investing Activities	-27	-4.86	0.84	-23	-7.76	-0.52	-9.41	-36	-4.69	-11	-17
Net Cash From Continuing Investing Activities	-27	-4.86	0.84	-23	-7.76	-0.52	-9.41	-36	-4.69	-11	-17
Purchase of Property, Plant & Equipment	-0.11	-2.38	-0.44	-1.35	-0.65	-3.05	-6.13	-2.37	-6.17	-4.35	-6.45
Purchase of Investments	-44	-3.74	-5.17	-24	-23	-14	-17	-14	-5.77	-19	-20
Sale and/or Maturity of Investments	17	1.10	6.45	2.87	16	16	14	13	7.25	12	9.38
Net Cash From Financing Activities	-0.91	47	-0.44	-0.39	14	31	14	0.35	11	23	39
Net Cash From Continuing Financing Activities	-0.91	47	-0.44	-0.39	14	31	14	0.35	11	23	39
Repayment of Debt	-	-	0.00	-	-0.20	-0.30	-0.30	-0.30	-0.30	-0.31	-58
Issuance of Common Equity	-	-	0.00	-	15	32	14	1.13	12	23	97
Other Financing Activities, net	-0.91	-1.45	-0.44	-0.39	-0.42	-1.08	0.12	-0.49	-0.73	0.66	-0.44
Cash Interest Paid	0.17	1.93	2.02	2.01	2.04	0.61	1.60	1.61	1.63	1.58	1.75
Cash Income Taxes Paid	0.18	0.29	0.30	0.26	0.35	0.26	0.21	0.71	0.12	0.24	0.75

This table presents GeneDx's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	252	554	491	419	419	524
Total Current Assets	174	484	213	182	198	268
Cash & Equivalents	108	401	124	100	85	105
Short-Term Investments	-	-	0.00	30	56	66
Accounts Receivable	32	27	43	33	38	74
Inventories, net	25	33	14	8.78	11	14
Prepaid Expenses	4.56	19	32	11	8.50	8.69
Plant, Property, & Equipment, net	63	63	52	32	33	46
Total Noncurrent Assets	14	7.83	227	204	189	210
Goodwill	-	-	-	-	0.00	14
Intangible Assets	-	0.00	187	173	159	168
Other Noncurrent Operating Assets	14	7.83	40	31	30	28
Total Liabilities & Shareholders' Equity	252	554	491	419	419	524
Total Liabilities	247	166	237	191	174	216
Total Current Liabilities	73	101	144	59	55	109
Accounts Payable	28	47	85	37	31	58
Other Current Liabilities	30	34	59	21	24	51
Total Noncurrent Liabilities	174	65	93	132	119	107
Long-Term Debt	19	11	6.25	53	52	48
Capital Lease Obligations	21	0.00	60	63	61	56
Noncurrent Deferred & Payable Income Tax Liabilities	-	0.00	2.66	1.56	0.97	0.76
Other Noncurrent Operating Liabilities	2.07	54	24	15	5.52	1.64
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-330	388	254	228	245	308
Total Preferred & Common Equity	-330	388	254	228	245	308
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-330	388	254	228	245	308
Common Stock	0.00	964	1,378	1,528	1,597	1,681
Retained Earnings	-330	-575	-1,124	-1,300	-1,352	-1,373
Accumulated Other Comprehensive Income / (Loss)	-	-	0.00	0.43	0.83	0.94

This table presents GeneDx's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	829	545	476	417	395	389	409	446	464	494	506
Total Current Assets	307	272	213	172	163	162	186	226	205	238	271
Cash & Equivalents	191	202	157	87	84	56	58	100	74	96	94
Short-Term Investments	-	-	-	27	29	51	59	59	60	59	77
Accounts Receivable	44	34	34	32	29	26	38	46	48	61	77
Inventories, net	44	12	12	9.35	12	10	11	13	12	11	12
Prepaid Expenses	18	12	11	16	9.97	19	20	8.01	10	11	11
Plant, Property, & Equipment, net	84	50	43	36	31	31	31	36	40	42	50
Total Noncurrent Assets	438	223	220	210	200	196	191	184	219	214	186
Goodwill	181	-	-	-	-	-	-	-	13	13	1.64
Intangible Assets	190	183	180	176	169	166	162	155	177	173	145
Other Noncurrent Operating Assets	66	40	40	34	31	30	29	29	29	29	39
Total Liabilities & Shareholders' Equity	829	545	476	417	395	389	409	446	464	494	506
Total Liabilities	268	217	180	163	187	195	204	189	187	202	252
Total Current Liabilities	162	119	84	68	51	68	77	70	71	88	88
Accounts Payable	89	74	55	39	32	52	56	42	49	50	47
Other Current Liabilities	74	45	30	29	18	16	21	28	22	37	41
Total Noncurrent Liabilities	105	98	96	95	137	127	127	119	115	114	165
Long-Term Debt	11	6.25	6.25	6.05	52	52	52	52	52	52	97
Capital Lease Obligations	62	64	64	64	62	61	60	60	60	57	66
Noncurrent Deferred & Payable Income Tax Liabilities	2.60	2.51	2.25	2.06	1.42	1.17	1.05	1.15	0.75	1.03	1.40
Other Noncurrent Operating Liabilities	30	25	24	23	21	13	14	6.62	3.28	4.26	0.07
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	561	328	296	254	207	194	205	257	277	292	254
Total Preferred & Common Equity	561	328	296	254	207	194	205	257	277	292	254
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	561	328	296	254	207	194	205	257	277	292	254
Common Stock	1,377	1,514	1,528	1,529	1,527	1,543	1,561	1,616	1,625	1,647	1,690
Retained Earnings	-816	-1,185	-1,232	-1,274	-1,320	-1,350	-1,358	-1,359	-1,348	-1,356	-1,437
Accumulated Other Comprehensive Income / (Loss)	-	-	-	-	0.29	0.46	0.92	0.91	0.81	1.00	0.68

This table displays calculated financial ratios and metrics derived from GeneDx's official financial filings.

Metric	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-
Revenue Growth	0.00%	-8.59%	18.33%	10.60%	-13.69%	50.79%	39.97%
EBITDA Growth	0.00%	-868.59%	3.02%	-143.73%	73.01%	80.97%	123.97%
EBIT Growth	0.00%	-700.33%	-1.36%	-146.20%	70.04%	72.29%	62.50%
NOPAT Growth	0.00%	-695.69%	-84.36%	-49.65%	72.95%	87.15%	43.67%
Net Income Growth	0.00%	-712.48%	-1.68%	-123.72%	67.98%	70.25%	59.80%
EPS Growth	0.00%	82.19%	100.00%	-123.72%	86.52%	73.17%	62.37%
Operating Cash Flow Growth	0.00%	-397.27%	-104.49%	-67.59%	43.56%	84.18%	216.78%
Free Cash Flow Firm Growth	0.00%	0.00%	-240.96%	-79.05%	78.36%	86.34%	-69.90%
Invested Capital Growth	0.00%	0.00%	97.58%	13,472.10%	8.91%	1.59%	11.17%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	1.54%	-1.90%	14.30%	6.30%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	-81.56%	63.68%	52.69%	-77.25%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	-82.20%	61.23%	38.70%	-456.01%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	-45.60%	62.36%	59.74%	-210.57%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	-95.78%	61.69%	37.38%	-1,109.17%
EPS Q/Q Growth	0.00%	0.00%	0.00%	-95.78%	59.36%	37.01%	-1,142.86%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	-21.46%	-4.13%	16.19%	48.35%	0.28%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-39.87%	36.43%	10.24%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	-55.74%	1.71%	8.21%	-1.95%
Profitability Metrics	-	-	-	-	-	-	-
Gross Margin	42.20%	2.25%	-7.82%	-11.40%	44.43%	63.64%	69.74%
EBITDA Margin	-11.98%	-126.94%	-104.04%	-229.26%	-71.70%	-9.05%	1.55%
Operating Margin	-15.50%	-134.95%	-210.25%	-284.48%	-89.15%	-7.60%	-3.06%
EBIT Margin	-15.25%	-133.49%	-114.34%	-254.53%	-88.35%	-16.24%	-4.35%
Profit (Net Income) Margin	-15.14%	-134.58%	-115.64%	-233.91%	-86.77%	-17.12%	-4.92%
Tax Burden Percent	100.00%	100.00%	100.00%	91.80%	99.48%	99.35%	99.45%
Interest Burden Percent	99.31%	100.82%	101.14%	100.11%	98.72%	106.11%	113.65%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	-480.40%	-61.74%	-7.55%	-4.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	-443.90%	74.98%	160.55%	20.88%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	309.33%	-11.24%	-14.55%	-3.60%
Return on Equity (ROE)	0.00%	-5,500.00%	-125.04%	-171.07%	-72.97%	-22.10%	-7.60%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	-339.15%	-70.26%	-9.13%	-14.58%
Operating Return on Assets (OROA)	0.00%	-95.12%	-60.23%	-114.32%	-39.35%	-11.84%	-3.94%
Return on Assets (ROA)	0.00%	-95.91%	-60.91%	-105.06%	-38.64%	-12.48%	-4.46%
Return on Common Equity (ROCE)	0.00%	413,692.00%	-18.49%	-171.07%	-72.97%	-22.10%	-7.60%
Return on Equity Simple (ROE_SIMPLE)	0.00%	73.12%	-63.23%	-216.39%	-77.09%	-21.32%	0.00%
Net Operating Profit after Tax (NOPAT)	-21	-169	-312	-467	-126	-16	-9.15
NOPAT Margin	-10.85%	-94.46%	-147.18%	-199.13%	-62.41%	-5.32%	-2.14%
Net Nonoperating Expense Percent (NNEP)	0.00%	-221.79%	29.45%	-36.50%	-136.72%	-168.10%	-24.88%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-36.79%	-4.54%	-2.22%
Cost of Revenue to Revenue	57.80%	97.75%	107.82%	111.40%	55.57%	36.36%	30.26%
SG&A Expenses to Revenue	15.03%	56.18%	97.07%	92.11%	66.03%	33.10%	35.28%
R&D to Revenue	17.80%	40.54%	49.56%	36.73%	28.76%	14.97%	16.85%
Operating Expenses to Revenue	57.70%	137.19%	202.43%	273.08%	133.59%	71.24%	72.80%
Earnings before Interest and Taxes (EBIT)	-30	-239	-243	-597	-179	-50	-19
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-24	-228	-221	-538	-145	-28	6.63
Valuation Ratios	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	2.77	0.40	0.31	8.61	12.20
Price to Tangible Book Value (P/TBV)	0.00	0.00	2.77	1.52	1.29	24.37	29.79
Price to Revenue (P/Rev)	1.96	3.41	5.07	0.43	0.35	6.91	8.79
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.23	0.27	9.60	15.31
Enterprise Value to Revenue (EV/Rev)	0.00	4.91	3.24	0.19	0.28	6.82	8.64
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	557.24
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	110.95
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-
Debt to Equity	0.00	9.86	0.03	0.26	0.51	0.46	0.34
Long-Term Debt to Equity	0.00	9.06	0.03	0.26	0.51	0.46	0.34
Financial Leverage	0.00	-14.79	-1.16	-0.70	-0.15	-0.09	-0.17
Leverage Ratio	0.00	57.35	2.05	1.63	1.89	1.77	1.70
Compound Leverage Factor	0.00	57.82	2.08	1.63	1.86	1.88	1.94
Debt to Total Capital	0.00%	90.79%	2.76%	20.71%	33.65%	31.51%	25.27%
Short-Term Debt to Total Capital	0.00%	7.36%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	83.43%	2.76%	20.71%	33.65%	31.51%	25.27%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	701.97%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	-692.76%	97.24%	79.29%	66.35%	68.49%	74.73%
Debt to EBITDA	0.00	-0.19	-0.05	-0.12	-0.80	-4.08	15.73
Net Debt to EBITDA	0.00	0.29	1.76	0.11	0.10	1.03	-10.12
Long-Term Debt to EBITDA	0.00	-0.17	-0.05	-0.12	-0.80	-4.08	15.73
Debt to NOPAT	0.00	-0.26	-0.04	-0.14	-0.91	-6.94	-11.39
Net Debt to NOPAT	0.00	0.38	1.25	0.12	0.11	1.74	7.33
Long-Term Debt to NOPAT	0.00	-0.23	-0.04	-0.14	-0.91	-6.94	-11.39
Altman Z-Score	0.00	-2.30	2.20	-6.32	-4.70	3.51	7.86
Noncontrolling Interest Sharing Ratio	0.00%	7,621.67%	85.21%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-
Current Ratio	0.00	2.37	4.77	1.47	3.10	3.61	2.46
Quick Ratio	0.00	1.91	4.22	1.16	2.77	3.26	2.26
Cash Flow Metrics	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-109	-371	-665	-144	-20	-33
Operating Cash Flow to CapEx	-121.17%	-291.26%	-916.16%	-2,228.42%	-10,742.22%	-518.96%	175.00%
Free Cash Flow to Firm to Interest Expense	0.00	-44.02	-130.98	-998.28	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-23.92	-37.64	-67.17	-479.21	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-43.66	-50.57	-74.50	-500.72	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-
Asset Turnover	0.00	0.71	0.53	0.45	0.45	0.73	0.91
Accounts Receivable Turnover	0.00	5.55	7.21	6.71	5.32	8.67	7.63
Inventory Turnover	0.00	7.02	7.83	11.10	10.03	11.43	10.52
Fixed Asset Turnover	0.00	2.84	3.37	4.11	4.82	9.35	10.88
Accounts Payable Turnover	0.00	6.22	6.06	3.96	1.84	3.29	2.92
Days Sales Outstanding (DSO)	0.00	65.81	50.65	54.36	68.61	42.09	47.81
Days Inventory Outstanding (DIO)	0.00	51.98	46.60	32.89	36.39	31.93	34.71
Days Payable Outstanding (DPO)	0.00	58.64	60.21	92.28	198.35	110.93	125.03
Cash Conversion Cycle (CCC)	0.00	59.15	37.05	-5.03	-93.35	-36.91	-42.52
Capital & Investment Metrics	-	-	-	-	-	-	-
Invested Capital	0.00	-60	-1.47	196	213	217	241
Invested Capital Turnover	0.00	-5.93	-6.85	2.41	0.99	1.42	1.87
Increase / (Decrease) in Invested Capital	0.00	-60	59	198	17	3.40	24
Enterprise Value (EV)	0.00	881	686	44	57	2,083	3,692
Market Capitalization	385	611	1,076	102	71	2,111	3,759
Book Value per Share	$0.00	($5.96)	$1.61	$0.66	$8.81	$8.93	$10.66
Tangible Book Value per Share	$0.00	($5.96)	$1.61	$0.17	$2.14	$3.15	$4.37
Total Capital	0.00	48	399	320	344	358	412
Total Debt	0.00	43	11	66	116	113	104
Total Long-Term Debt	0.00	40	11	66	116	113	104
Net Debt	0.00	-65	-390	-58	-15	-28	-67
Capital Expenditures (CapEx)	15	32	21	14	1.68	5.49	19
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-3.96	-18	-56	-6.63	1.97	-12
Debt-free Net Working Capital (DFNWC)	0.00	104	382	68	124	143	159
Net Working Capital (NWC)	0.00	101	382	68	124	143	159
Net Nonoperating Expense (NNE)	8.41	72	-67	82	49	36	12
Net Nonoperating Obligations (NNO)	0.00	-65	-390	-58	-15	-28	-67
Total Depreciation and Amortization (D&A)	6.41	12	22	59	34	22	25
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-2.21%	-8.63%	-23.69%	-3.27%	0.64%	-2.78%
Debt-free Net Working Capital to Revenue	0.00%	58.09%	180.15%	29.11%	60.98%	46.87%	37.28%
Net Working Capital to Revenue	0.00%	56.14%	180.15%	29.11%	60.98%	46.87%	37.28%
Earnings Adjustments	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	$0.00	($53.79)	($7.23)	($1.94)	($0.73)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	0.00	10.24M	24.31M	26.89M	28.64M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	($53.79)	($7.23)	($1.94)	($0.73)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	0.00	10.24M	24.31M	26.89M	28.64M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	0.00	24.19M	26.05M	28.07M	29.29M
Normalized Net Operating Profit after Tax (NOPAT)	-21	-169	-312	-320	-119	-16	-9.15
Normalized NOPAT Margin	-10.85%	-94.46%	-147.18%	-136.46%	-58.81%	-5.32%	-2.14%
Pre Tax Income Margin	-15.14%	-134.58%	-115.64%	-254.81%	-87.23%	-17.23%	-4.94%
Debt Service Ratios	-	-	-	-	-	-	-
EBIT to Interest Expense	-38.20	-96.76	-85.59	-896.95	0.00	0.00	0.00
NOPAT to Interest Expense	-27.19	-68.47	-110.16	-701.74	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-57.94	-109.68	-92.92	-918.45	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-46.93	-81.39	-117.49	-723.24	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	-21.09%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	-21.09%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from GeneDx's official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	29,288,739.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	29,288,739.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-2.16
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-35.96%	-6.41%	44.70%	44.77%	44.22%	66.57%	39.56%	45.63%	51.86%	26.50%	17.38%
EBITDA Growth	48.16%	92.62%	72.41%	38.26%	95.44%	157.54%	101.63%	175.57%	77.82%	-192.79%	-20,577.97%
EBIT Growth	44.10%	91.46%	67.72%	40.68%	82.73%	123.17%	72.41%	139.97%	9.18%	-389.76%	-913.18%
NOPAT Growth	52.69%	92.11%	77.37%	79.51%	81.89%	149.28%	66.68%	223.81%	58.21%	-212.66%	-1,162.82%
Net Income Growth	45.49%	91.65%	66.82%	37.56%	80.34%	121.10%	67.74%	137.05%	8.14%	-424.86%	-869.77%
EPS Growth	75.60%	96.49%	74.34%	40.22%	81.10%	118.87%	70.51%	132.73%	12.90%	-395.00%	-839.13%
Operating Cash Flow Growth	53.34%	53.82%	70.46%	91.58%	89.34%	89.34%	162.04%	331.30%	458.75%	2.92%	-418.29%
Free Cash Flow Firm Growth	135.89%	91.67%	76.63%	-98.95%	-98.02%	115.38%	86.57%	-2,436.08%	-1,290.00%	-727.84%	-1,600.55%
Invested Capital Growth	-52.61%	8.91%	13.04%	-4.45%	-4.51%	1.59%	0.64%	26.85%	22.68%	11.17%	17.41%
Revenue Q/Q Growth	9.44%	7.72%	8.72%	12.96%	9.02%	24.41%	-8.91%	17.88%	13.68%	3.64%	-15.48%
EBITDA Q/Q Growth	7.48%	41.78%	24.26%	-60.62%	93.17%	835.35%	-97.98%	7,345.34%	-102.00%	-2,976.42%	-346.28%
EBIT Q/Q Growth	9.33%	39.38%	21.75%	-44.34%	73.60%	181.32%	-189.04%	309.11%	-159.98%	-159.45%	-211.33%
NOPAT Q/Q Growth	16.77%	40.32%	46.73%	22.55%	26.46%	262.41%	-136.02%	387.81%	-124.82%	-337.87%	-303.73%
Net Income Q/Q Growth	9.49%	39.05%	21.47%	-44.14%	71.51%	165.42%	-220.06%	265.55%	-170.64%	-131.38%	-258.41%
EPS Q/Q Growth	10.87%	35.37%	26.42%	-41.03%	71.82%	164.52%	-215.00%	256.52%	-175.00%	-118.52%	-266.10%
Operating Cash Flow Q/Q Growth	22.94%	27.58%	45.03%	72.55%	2.44%	27.58%	419.89%	2.34%	51.31%	-119.60%	-948.80%
Free Cash Flow Firm Q/Q Growth	12.22%	-117.45%	5.04%	105.67%	110.31%	35.74%	-182.90%	-887.12%	-7.13%	28.38%	-124.54%
Invested Capital Q/Q Growth	0.21%	1.71%	-2.28%	-4.07%	0.15%	8.21%	-3.20%	20.92%	-3.14%	-1.95%	2.23%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	47.39%	53.56%	59.93%	60.91%	62.22%	69.22%	67.13%	69.04%	72.40%	69.65%	66.71%
EBITDA Margin	-65.36%	-35.32%	-23.19%	-32.97%	-2.06%	12.20%	0.27%	17.11%	-0.30%	-8.95%	-47.26%
Operating Margin	-80.61%	-44.66%	-21.88%	-15.00%	-10.12%	9.21%	-5.22%	8.73%	-2.78%	-11.77%	-56.20%
EBIT Margin	-81.63%	-45.94%	-31.60%	-40.37%	-9.78%	6.39%	-6.25%	11.08%	-5.85%	-14.64%	-53.92%
Profit (Net Income) Margin	-79.33%	-44.89%	-32.42%	-41.37%	-10.81%	5.69%	-7.49%	10.53%	-6.54%	-14.60%	-61.92%
Tax Burden Percent	99.59%	98.43%	99.60%	99.35%	99.44%	100.44%	107.35%	102.33%	103.34%	96.91%	101.44%
Interest Burden Percent	97.58%	99.27%	103.03%	103.14%	111.22%	88.58%	111.76%	92.82%	108.23%	102.94%	113.21%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	-0.44%	0.00%	-2.33%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-35.70%	-30.93%	-17.29%	-12.49%	-9.23%	13.13%	-5.77%	14.25%	-3.51%	-15.38%	-76.31%
ROIC Less NNEP Spread (ROIC-NNEP)	-20.69%	-9.25%	-2.30%	41.55%	2.61%	29.02%	8.76%	-4.87%	17.75%	0.77%	7.53%
Return on Net Nonoperating Assets (RNNOA)	4.13%	1.39%	0.61%	-6.83%	-0.28%	-2.63%	-0.87%	0.18%	-1.80%	-0.13%	-0.81%
Return on Equity (ROE)	-31.57%	-29.54%	-16.67%	-19.32%	-9.50%	10.50%	-6.64%	14.43%	-5.31%	-15.51%	-77.12%
Cash Return on Invested Capital (CROIC)	-31.51%	-70.26%	-59.91%	-27.19%	-15.06%	-9.13%	-5.35%	-21.48%	-16.66%	-14.58%	-36.25%
Operating Return on Assets (OROA)	-27.05%	-20.46%	-14.92%	-22.73%	-6.33%	4.66%	-4.90%	9.41%	-5.21%	-13.27%	-50.11%
Return on Assets (ROA)	-26.29%	-19.99%	-15.31%	-23.29%	-7.00%	4.14%	-5.88%	8.94%	-5.83%	-13.24%	-57.54%
Return on Common Equity (ROCE)	-31.57%	-29.54%	-16.67%	-19.32%	-9.50%	10.50%	-6.64%	14.43%	-5.31%	-15.51%	-77.12%
Return on Equity Simple (ROE_SIMPLE)	-180.43%	0.00%	-65.16%	-60.54%	-40.83%	0.00%	-14.99%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-30	-18	-9.56	-7.41	-5.45	8.85	-3.19	9.17	-2.28	-9.96	-40
NOPAT Margin	-56.43%	-31.26%	-15.32%	-10.50%	-7.08%	9.25%	-3.66%	8.93%	-1.95%	-8.24%	-39.34%
Net Nonoperating Expense Percent (NNEP)	-15.01%	-21.67%	-14.99%	-54.04%	-11.84%	-15.89%	-14.52%	19.12%	-21.27%	-16.14%	-83.84%
Return On Investment Capital (ROIC_SIMPLE)	-	-5.22%	-	-	-	2.47%	-0.86%	2.36%	-0.57%	-2.42%	-9.64%
Cost of Revenue to Revenue	52.61%	46.44%	40.07%	39.09%	37.78%	30.78%	32.87%	30.96%	27.60%	30.35%	33.29%
SG&A Expenses to Revenue	48.96%	46.37%	35.96%	35.70%	34.01%	28.60%	36.89%	26.70%	38.07%	38.71%	72.95%
R&D to Revenue	26.81%	21.33%	18.53%	15.46%	15.17%	12.12%	14.44%	14.68%	16.99%	20.28%	19.37%
Operating Expenses to Revenue	128.00%	98.22%	81.82%	75.92%	72.34%	60.02%	72.35%	60.32%	75.19%	81.41%	122.91%
Earnings before Interest and Taxes (EBIT)	-44	-26	-20	-28	-7.52	6.11	-5.44	11	-6.83	-18	-55
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-35	-20	-14	-23	-1.59	12	0.24	18	-0.35	-11	-48
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.37	0.31	1.14	3.52	5.59	8.61	9.66	9.50	10.59	12.20	7.40
Price to Tangible Book Value (P/TBV)	1.20	1.29	6.20	24.04	26.96	24.37	24.30	30.10	28.96	29.79	17.49
Price to Revenue (P/Rev)	0.45	0.35	1.07	2.80	4.28	6.91	7.53	7.27	7.70	8.79	4.25
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1,873.33	1,485.82	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.05%	0.07%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.24	0.27	1.14	3.44	5.68	9.60	11.61	10.28	12.40	15.31	7.60
Enterprise Value to Revenue (EV/Rev)	0.24	0.28	1.07	2.83	4.26	6.82	7.39	7.21	7.58	8.64	4.23
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	93.61	104.67	557.24	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	575.79	583.58	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	524.75	368.24	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	200.45	91.86	110.95	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.28	0.51	0.55	0.58	0.55	0.46	0.43	0.40	0.37	0.34	0.64
Long-Term Debt to Equity	0.28	0.51	0.55	0.58	0.55	0.46	0.43	0.40	0.37	0.34	0.64
Financial Leverage	-0.20	-0.15	-0.27	-0.16	-0.11	-0.09	-0.10	-0.04	-0.10	-0.17	-0.11
Leverage Ratio	1.53	1.89	1.75	1.77	1.80	1.77	1.81	1.81	1.82	1.70	1.86
Compound Leverage Factor	1.49	1.87	1.81	1.82	2.00	1.57	2.02	1.68	1.97	1.75	2.11
Debt to Total Capital	21.57%	33.65%	35.55%	36.79%	35.47%	31.51%	30.26%	28.65%	27.12%	25.27%	39.09%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	21.57%	33.65%	35.55%	36.79%	35.47%	31.51%	30.26%	28.65%	27.12%	25.27%	39.09%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	78.43%	66.35%	64.45%	63.21%	64.53%	68.49%	69.74%	71.35%	72.88%	74.73%	60.91%
Debt to EBITDA	-0.17	-0.80	-1.08	-1.23	-1.92	-4.08	-8.64	3.99	3.73	15.73	-3.89
Net Debt to EBITDA	0.11	0.10	-0.01	-0.07	0.07	1.03	3.67	-0.83	-1.59	-10.12	0.18
Long-Term Debt to EBITDA	-0.17	-0.80	-1.08	-1.23	-1.92	-4.08	-8.64	3.99	3.73	15.73	-3.89
Debt to NOPAT	-0.21	-0.91	-1.22	-1.74	-2.78	-6.94	-11.32	22.37	13.13	-11.39	-3.53
Net Debt to NOPAT	0.13	0.11	-0.02	-0.09	0.10	1.74	4.81	-4.67	-5.60	7.33	0.17
Long-Term Debt to NOPAT	-0.21	-0.91	-1.22	-1.74	-2.78	-6.94	-11.32	22.37	13.13	-11.39	-3.53
Altman Z-Score	-3.48	-3.49	-3.19	-2.08	-0.38	3.95	4.75	5.60	6.50	7.86	1.45
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.51	3.10	3.22	2.38	2.41	3.61	3.25	2.87	2.71	2.46	3.09
Quick Ratio	2.15	2.77	2.80	1.95	2.00	3.26	2.95	2.56	2.47	2.26	2.83
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	203	-35	-34	1.91	4.01	5.45	-4.51	-45	-48	-34	-77
Operating Cash Flow to CapEx	0.00%	-1,339.52%	-3,704.97%	-333.21%	-680.34%	-104.36%	166.13%	439.85%	255.46%	-71.08%	-502.22%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	-56.33	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-11.69
Operating Cash Flow to Interest Expense	0.00	0.00	-27.49	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-4.94
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	-28.23	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-5.92
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.33	0.45	0.47	0.56	0.65	0.73	0.79	0.85	0.89	0.91	0.93
Accounts Receivable Turnover	5.42	5.32	7.10	8.11	7.54	8.67	8.81	9.76	8.09	7.63	7.20
Inventory Turnover	6.11	10.03	9.16	9.82	10.76	11.43	9.45	10.69	11.44	10.52	10.82
Fixed Asset Turnover	3.44	4.82	5.49	6.53	7.95	9.35	9.76	10.14	10.89	10.88	10.23
Accounts Payable Turnover	2.56	1.84	2.06	2.01	2.27	3.29	3.09	2.35	2.29	2.92	3.05
Days Sales Outstanding (DSO)	67.41	68.61	51.39	45.01	48.41	42.09	41.41	37.38	45.11	47.81	50.67
Days Inventory Outstanding (DIO)	59.72	36.39	39.85	37.18	33.91	31.93	38.63	34.16	31.90	34.71	33.72
Days Payable Outstanding (DPO)	142.35	198.35	177.42	181.56	160.60	110.93	118.19	155.32	159.58	125.03	119.74
Cash Conversion Cycle (CCC)	-15.23	-93.35	-86.17	-99.37	-78.28	-36.91	-38.15	-83.78	-82.57	-42.52	-35.35
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	210	213	209	200	200	217	210	254	246	241	247
Invested Capital Turnover	0.63	0.99	1.13	1.19	1.30	1.42	1.58	1.60	1.80	1.87	1.94
Increase / (Decrease) in Invested Capital	-233	17	24	-9.31	-9.46	3.40	1.33	54	45	24	37
Enterprise Value (EV)	49	57	238	689	1,139	2,083	2,438	2,611	3,049	3,692	1,873
Market Capitalization	94	71	236	683	1,143	2,111	2,486	2,634	3,095	3,759	1,881
Book Value per Share	$9.87	$8.81	$7.95	$7.42	$7.59	$8.93	$9.17	$9.71	$10.17	$10.66	$8.68
Tangible Book Value per Share	$3.03	$2.14	$1.46	$1.09	$1.57	$3.15	$3.65	$3.07	$3.72	$4.37	$3.67
Total Capital	324	344	322	307	317	358	369	388	401	412	417
Total Debt	70	116	114	113	112	113	112	111	109	104	163
Total Long-Term Debt	70	116	114	113	112	113	112	111	109	104	163
Net Debt	-44	-15	1.41	6.10	-4.06	-28	-47	-23	-46	-67	-7.62
Capital Expenditures (CapEx)	-0.14	2.23	0.44	1.35	0.65	3.05	6.13	2.37	6.17	4.35	6.45
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-11	-6.63	-0.22	-13	-7.79	1.97	-2.89	-1.13	-5.12	-12	12
Debt-free Net Working Capital (DFNWC)	103	124	113	94	109	143	156	133	150	159	183
Net Working Capital (NWC)	103	124	113	94	109	143	156	133	150	159	183
Net Nonoperating Expense (NNE)	12	7.82	11	22	2.87	3.41	3.34	-1.64	5.36	7.70	23
Net Nonoperating Obligations (NNO)	-44	-15	1.41	6.10	-4.06	-28	-47	-23	-46	-67	-7.62
Total Depreciation and Amortization (D&A)	8.67	6.09	5.25	5.22	5.93	5.56	5.68	6.19	6.47	6.88	6.81
Debt-free, Cash-free Net Working Capital to Revenue	-5.25%	-3.27%	-0.10%	-5.32%	-2.92%	0.64%	-0.87%	-0.31%	-1.27%	-2.78%	2.78%
Debt-free Net Working Capital to Revenue	50.10%	60.98%	50.80%	38.54%	40.66%	46.87%	47.34%	36.83%	37.29%	37.28%	41.34%
Net Working Capital to Revenue	50.10%	60.98%	50.80%	38.54%	40.66%	46.87%	47.34%	36.83%	37.29%	37.28%	41.34%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.64)	($1.06)	($0.78)	($1.10)	($0.31)	$0.20	($0.23)	$0.38	($0.27)	($0.61)	($2.16)
Adjusted Weighted Average Basic Shares Outstanding	25.79M	24.31M	26.06M	26.62M	27.10M	26.89M	28.15M	28.58M	28.80M	28.64M	29.34M
Adjusted Diluted Earnings per Share	($1.64)	($1.06)	($0.78)	($1.10)	($0.31)	$0.20	($0.23)	$0.36	($0.27)	($0.59)	($2.16)
Adjusted Weighted Average Diluted Shares Outstanding	25.79M	24.31M	26.06M	26.62M	27.10M	26.89M	28.15M	29.75M	28.80M	28.64M	29.34M
Adjusted Basic & Diluted Earnings per Share	$0.00	($1.06)	$0.00	$0.00	$0.00	$0.20	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	25.88M	26.05M	26.14M	26.94M	27.47M	28.07M	28.53M	28.73M	28.90M	29.29M	29.69M
Normalized Net Operating Profit after Tax (NOPAT)	-24	-18	-9.56	-7.41	-5.45	6.16	-3.19	6.27	-2.28	-9.96	-18
Normalized NOPAT Margin	-45.55%	-31.26%	-15.32%	-10.50%	-7.08%	6.45%	-3.66%	6.11%	-1.95%	-8.24%	-17.92%
Pre Tax Income Margin	-79.65%	-45.60%	-32.55%	-41.64%	-10.87%	5.66%	-6.98%	10.29%	-6.33%	-15.07%	-61.04%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	-33.04	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-8.40
NOPAT to Interest Expense	0.00	0.00	-16.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-6.13
EBIT Less CapEx to Interest Expense	0.00	0.00	-33.78	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-9.38
NOPAT Less CapEx to Interest Expense	0.00	0.00	-16.76	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-7.11
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

GeneDx Holdings Corp. (NASDAQ: WGS) has shown a clear top-line growth trend over the last four years, with periodic swings in profitability and cash flow. Below is a concise, bulleted outlook focused on the most meaningful year-over-year trends from the quarterly statements provided.

Revenue growth momentum in 2025: Total revenue rose from about $87.1M in Q1 2025 to about $121.0M in Q4 2025, indicating strong year-end top-line momentum.
Gross margin improvement in 2025: Gross margin expanded to around 70% in late-2025 (gross profit of roughly $84.3M on $120.99M revenue in Q4 2025), up from mid-60s% in earlier periods.
Improving operating cash flow through 2025 (early-year strength): Operating cash flow was solid in Q1–Q3 2025 (roughly $10.2M, $10.4M, and $15.8M from continuing operations, respectively), signaling improving cash generation during the year.
Profitability in one quarter (Q2 2025) shows narrowing losses: Net income from continuing operations was positive in Q2 2025 (about $10.8M), highlighting a period of improved profitability relative to other quarters.
Liquidity supported by equity raises: The company continued to raise cash via common equity issuances across 2024–2025 (for example, notable issuances around $32.4M in Q4 2024 and $22.8M in Q4 2025, plus additional smaller raises in 2025), helping to bolster liquidity.
Balance sheet growth aligned with scale-up: Total assets increased to roughly $494M by Q3 2025 from the lower-figure range in 2022–2024, indicating ongoing scale-up alongside revenue growth.
Healthy cash balances across 2024–2025: Cash and equivalents generally trended around $95–100M in 2024–2025, supporting liquidity for operations and investing activities.
Net income remains largely negative across periods: Despite a +Q2 2025, several quarters show net losses (e.g., Q4 2025 net income around -$17.7M; Q3 2025 around -$7.6M; Q1 2025 around -$6.5M), highlighting ongoing profitability challenges.
Operating income frequently negative: The company reported negative operating income in multiple periods (e.g., Q4 2025 operating loss of about -$14.2M), signaling persistent pressure on core earnings even as revenue grows.
Cash flow from operating activities cooled in some quarters: Cash flow from continuing operating activities was negative in Q4 2024 and again in Q4 2025, pointing to episodic working-capital and operating-cycle headwinds despite improvement earlier in 2025.

05/12/26 02:31 PM ETAI Generated. May Contain Errors.

GeneDx Financials - Frequently Asked Questions

According to the most recent income statement we have on file, GeneDx's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

GeneDx's net income appears to be on a downward trend, with a most recent value of -$21.02 million in 2025, falling from -$29.70 million in 2019. The previous period was -$52.29 million in 2024. Find out what analysts predict for GeneDx in the coming months.

GeneDx's total operating income in 2025 was -$13.08 million, based on the following breakdown:

Total Gross Profit: $298.17 million
Total Operating Expenses: $311.25 million

Over the last 6 years, GeneDx's total revenue changed from $196.17 million in 2019 to $427.54 million in 2025, a change of 117.9%.

GeneDx's total liabilities were at $215.53 million at the end of 2025, a 23.8% increase from 2024, and a 12.8% decrease since 2020.

In the past 5 years, GeneDx's cash and equivalents has ranged from $85.21 million in 2024 to $400.57 million in 2021, and is currently $105.00 million as of their latest financial filing in 2025.

Over the last 6 years, GeneDx's book value per share changed from 0.00 in 2019 to 10.66 in 2025, a change of 1,066.2%.

Related Companies

Financial statements for NASDAQ:WGS last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GeneDx (WGS) Financials

Financials Breakdown Chart

Key Financial Trends

GeneDx Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GeneDx (WGS) Financials

Annual Income Statements for GeneDx

Quarterly Income Statements for GeneDx

Annual Cash Flow Statements for GeneDx

Quarterly Cash Flow Statements for GeneDx

Annual Balance Sheets for GeneDx

Quarterly Balance Sheets for GeneDx

Annual Metrics And Ratios for GeneDx

Quarterly Metrics And Ratios for GeneDx

Financials Breakdown Chart

Key Financial Trends

GeneDx Financials - Frequently Asked Questions

When does GeneDx's financial year end?

How has GeneDx's net income changed over the last 6 years?

What is GeneDx's operating income?

How has GeneDx's revenue changed over the last 6 years?

How much debt does GeneDx have?

How much cash does GeneDx have?

How has GeneDx's book value per share changed over the last 6 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools